The Global Human Papillomavirus Vaccine Market is estimated to be USD 3.69 Bn in 2023 and is expected to reach USD 5.09 Bn by 2028 growing at a CAGR of 6.61%.
However, stringent government regulations associated with manufacturing new vaccines and a lower adoption rate of vaccines are anticipated to hamper market growth.
2. The HPV vaccine, Cecolin by Innovax is officially accepted by WHO for the prequalification evaluation. - 18th March 2020.
Market Dynamics
There are more than 100 HPV, among which 14 are cancer-causing. According to WHO, HVP 16 and 18 types are responsible for around 70% of cervical cancer and pre-cancerous cervical lesions. The rising incidences of human papillomavirus (HPV) associated cancers of the anus, vulva, vagina, penis, and oropharynx and increasing demand for prevention of these infections are majorly driving the HPV vaccine market. In addition, government initiatives in HPV vaccination programs are anticipated to propel market growth. Since June 2020, around 55% of the WHO Member States have introduced HPV vaccination. Furthermore, increasing healthcare infrastructure and expenditure in emerging countries is expected to generate untapped opportunities for the market participants.However, stringent government regulations associated with manufacturing new vaccines and a lower adoption rate of vaccines are anticipated to hamper market growth.
Market Segmentation
- The Global Human Papillomavirus Vaccine Market is segmented further based on Type, Indication, Diseases, and Geography.
- By Type, the market is classified into bivalent, quadrivalent, and nonavalent. Amongst all, the bivalent segment is estimated to hold the highest market share during the forecast period.
- By Indication, the market is classified as cervical cancer, anal cancer, penile cancer, oropharyngeal cancer, genital warts, and others. Amongst all, the cervical cancer segment is estimated to hold the highest market share during the forecast period.
- By Diseases, the market is classified as systemic human papillomavirus vaccine and localized human papillomavirus vaccine. Amongst the two, the systemic human papillomavirus vaccine segment is estimated to hold the highest market share during the forecast period.
- By Geography, North America is projected to lead the market.
Recent Developments
1. U.S. Food and Drug Administration (FDA) approved an expanded indication for Mercks’ Gardasil 9-a human papillomavirus (HPV) nine-valent vaccine-for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. - 10th July 2020.2. The HPV vaccine, Cecolin by Innovax is officially accepted by WHO for the prequalification evaluation. - 18th March 2020.
Company Profiles
Some of the companies covered in this report Merck & Co., Inc., GlaxoSmithKline Plc, Sanofi S.A., Johnson & Johnson, AstraZeneca Plc, Serum Institute of India Pvt. Ltd., Bharat Biotech, etc.Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.Why buy this report?
- The report offers a comprehensive evaluation of the Global Human Papillomavirus Vaccine Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
- The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Human Papillomavirus Vaccine Market, By Type
7 Global Human Papillomavirus Vaccine Market, By Indication
8 Global Human Papillomavirus Vaccine Market, By Diseases
9 Global Human Papillomavirus Vaccine Market, By Geography
10 Competitive Landscape
11 Company Profiles
12 Appendix
Companies Mentioned
- Merck & Co., Inc.,
- A-S Medication Solutions LLC
- GlaxoSmithKline Plc
- Sanofi S.A.
- Johnson & Johnson
- AstraZeneca Plc
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Bavarian Nordic
- Inovio Pharmaceuticals
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 168 |
Published | February 2024 |
Forecast Period | 2023 - 2028 |
Estimated Market Value ( USD | $ 3.69 Billion |
Forecasted Market Value ( USD | $ 5.09 Billion |
Compound Annual Growth Rate | 6.6% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |